Some people notice reduced appetite within the first few days, while others experience a more gradual change over several weeks
Del Prato S, Kang J, Trautmann ME et al (2020) Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: results of a phase 2 placebo-controlled, 16-week randomized dose-finding study
What community members commonly report: Sustained energy improvements that persist after stopping injections Improved exercise tolerance and recovery Some report improved skin elasticity and reduced fine lines (subjective) Occasional reports of improved bloodwork markers (inflammatory markers, kidney function) Joint comfort improvements, particularly in those with pre-existing stiffness What to monitor: This is an appropriate time for follow-up bloodwork
On each visit, participants consumed either 0.5g/kg body mass KM or a non-caloric, taste-matched placebo, 30 minutes prior to each MMTT in a randomised, double-blind, crossover design
We start with a comprehensive health assessment to understand your needs
